With Sciety, you have the opportunity to invest alongside us in exceptional life science and digital health companies. We have strong deal flow across the Nordic region and a rigorous selection process grounded in deep industry expertise.
We work with companies that have the potential to become market leaders and drive meaningful change in their respective fields. Our engagement is long-term – beacuse we believe active ownership is key to creating value, both for the companies and for us as investors.
Interested in investing with us?
Sciety Venture Partners brings togheter experienced investors – from private investment firms and family offices to specialised investment companies – with a strong track record of investing in and supporting the growth of life science companies.
Sciety also has an extensive network of Nordic and European venture capital and corporate venture capital firms that co-invest with us.
We spoke with some of our members to learn what drives them to invest in and support the development of companies in the sector.
Sweden is Northern Europe’s most dynamic market for life sciences, with a strong focus on innovation and collaboration. It is in the top five among the world’s countries in terms of investment in research and development.
An aging population, increasing incidence of lifestyle diseases, and more demanding health care consumers are increasing demand for drugs, innovative medical technology, and digital solutions.
The biotechnological revolution creates new opportunities to develop customized treatments for each individual disease case. This in turn leads to increased demand for precision diagnostics and technology solutions in areas such as genomics.
Growth companies in the biopharma sector are behind the majority of all new drugs approved by the FDA. Increasing numbers of partnership agreements are also being signed between Big Pharma and smaller companies.
Digital solutions are being implemented at a fast pace. Efforts to streamline healthcare processes, cost savings, and improved health care quality as well as increased demand for on-demand care are drivers behind this trend.
Over the past 100 years, the global average life expectancy has more than doubled and is now 73 years. The child mortality rate in the world has declined by nearly 75% since 1950. Significant medical advances are one of the causes behind this positive development.
We’ve got you covered.
We have extensive experience in investing in and supporting the development of leading companies within life sciences and digital health. Over the years, we’ve built a strong network of Nordic and European specialist investors and well-capitalised partners who co-invest with us.
We lead the investment process from initial dialogue to funds in the bank – and we understand that time is critical. During the capital raise, our full attention is on your company, and we typically complete the first capital injection within just a few months.
Our commitment continues beyond the capital raise. We remain actively engaged, supporting each company based on its specific needs – whether that means making introductions to potential customers and strategic partners, or helping strenghten the board with relevant expertise. As a long-term partner, our goal is to strengthen your position ahead of future funding rounds, strategic collaborations, M&A or IPO.
PeptiSystems has developed a groundbreaking technology for the large-scale production of precision drugs. The company sells instruments for manufacturing peptides and oligonucleotides used in pharmaceutical manufacturing.
Akiram has developed a new type of targeted radioimmunotherapy with the potential to become first-in-class. In animal studies, the survival rate has been 100%, and the tumours have been eradicated with just one treatment.
Encare not only contributes to more cost-effective surgery but also reduces complications and saves lives through their proprietary software solution that helps hospitals implement best practice throughout the entire care chain – from diagnosis and preparation to surgery and rehabilitation.
The company has developed a DNA sequencing solution with significantly improved performance compared with current alternatives. The market is growing rapidly in terms of both research and clinical applications.
Sciety combines efficient processes and advanced tech solutions with deep expertise in life science to identify and support the most promising Nordic life science companies. Learn more about our data-driven approach to investing in a healthier future.
